The Motley Fool

3 Of The Best Turnaround Stocks: AstraZeneca plc, Debenhams Plc And Imagination Technologies Group plc

In recent years, Debenhams (LSE: DEB) has struggled to come to terms with a changing UK consumer landscape. With household budgets having come under sustained pressure from wage growth that has consistently fallen behind inflation, consumers have become increasingly price conscious and have traded down to lower-priced options. As such, mid-tier operators such as Debenhams have seen their sales and profitability come under pressure.

In response, Debenhams offered greater discounts and while this aided sales growth, it came at the expense of margins. As a result, its bottom line declined and this hurt investor sentiment.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

Now though, Debenhams has a new strategy focused on margins and it’s having a positive impact on the company’s bottom line. Last year Debenhams posted a rise in net profit of 3%, while further positive growth is forecast for this year and next. With the shares trading on a price-to-earnings (P/E) ratio of just 10.4, there’s significant upward rerating potential on the cards. And increasing household budgets (in real terms) are likely to provide Debenhams with a tailwind moving forward.

Potential in the pipeline

Also offering stunning turnaround prospects is pharmaceuticals company AstraZeneca (LSE: AZN). Like Debenhams, it has endured a difficult period, with the company’s pipeline of new drugs failing to fully offset the loss of patents on key blockbuster drugs. Due to this, AstraZeneca’s bottom line has posted a sustained fall in recent years, with this trend likely to continue in the near term.

However, after multiple major acquisitions, AstraZeneca’s drug pipeline now offers huge long-term appeal. Evidence of this can be seen in the bid rumours for the company that have persisted in the last couple of years. Although a bid would equate to a high short-term gain in the company’s share price, AstraZeneca’s drug pipeline has the potential to deliver even higher returns in the long run. And with its shares trading on a P/E ratio of 14.9, they seem to offer good value for money given their turnaround potential.

Big change ahead

Meanwhile, Imagination Technologies (LSE: IMG) is another company with huge turnaround potential. Clearly, it remains a relatively high-risk play as it’s now expected to post a loss for the current financial year. Furthermore, there are major changes ongoing at the company following its profit warning and they equate to great uncertainty regarding Imagination Technologies’ future prospects.

Notably, the company is searching for a new CEO and he/she is likely to bring a revised strategy that could impact on investor sentiment in the short run. And with it being in the process of a major restructuring that includes asset disposals, Imagination Technologies could be a very different company with a vastly changed business model in a year or two’s time.

But with a return to profit forecast for next year and a price-to-earnings growth (PEG) ratio of 0.8, it may be worth buying for less risk-averse investors.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

Peter Stephens owns shares of AstraZeneca and Debenhams. The Motley Fool UK owns shares of Imagination Technologies. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

The renowned analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply enter your email address below to discover how you can take advantage of this.

I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement.